Literature DB >> 16214306

The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model.

Gary E Duncan1, Harold Kohn.   

Abstract

Brain metabolic activation after 6 Hz electrical stimulation (32 mA, 3s stimulus duration) was assessed by autoradiographic analysis of 14C-2-deoxyglucose (2-DG) uptake. In addition, effects of the new antiepileptic drug lacosamide were examined on the stimulation-induced metabolic activation. The 6 Hz stimulation via corneal electrodes induced a robust increase 2-DG uptake in cerebral cortical regions, lateral amygdala, and the caudate-putamen. Many other brain regions were not affected by the stimulation, including the hippocampal formation, medial nuclei of the amygdala, thalamus, and hypothalamus. Lacosamide (20 mg/kg) injected i.p. 30 min before application of electrical stimulation antagonized completely the seizure-induced brain metabolic activation but did not affect basal 2-DG uptake. The data provide evidence that lacosamide antagonizes the neural activation induced by an electrical seizure stimulus, without suppressing normal brain metabolic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214306     DOI: 10.1016/j.eplepsyres.2005.08.009

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  12 in total

Review 1.  Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.

Authors:  Juan Luis Becerra; Joaquín Ojeda; Enrique Corredera; Jesús Ruiz Giménez
Journal:  CNS Drugs       Date:  2011-12-05       Impact factor: 5.749

Review 2.  Lacosamide.

Authors:  Pamela Doty; G David Rudd; Thomas Stoehr; Dirk Thomas
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 3.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 4.  Pharmacotherapy of epilepsy: newly approved and developmental agents.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

5.  Clinical perspectives on lacosamide.

Authors:  Jonathan J Halford; Marc Lapointe
Journal:  Epilepsy Curr       Date:  2009 Jan-Feb       Impact factor: 7.500

Review 6.  Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.

Authors:  Sarah M Wilson; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

7.  Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders.

Authors:  Giulia Curia; Giuseppe Biagini; Emilio Perucca; Massimo Avoli
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Development of lacosamide for the treatment of partial-onset seizures.

Authors:  Pamela Doty; David Hebert; Francois-Xavier Mathy; William Byrnes; James Zackheim; Kelly Simontacchi
Journal:  Ann N Y Acad Sci       Date:  2013-07       Impact factor: 5.691

9.  Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.

Authors:  Christoph Kellinghaus
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

10.  Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy.

Authors:  Adriana Monserrath Orellana-Paucar; Tatiana Afrikanova; Joice Thomas; Yelaman K Aibuldinov; Wim Dehaen; Peter A M de Witte; Camila V Esguerra
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.